Dexelvucitabine

Dexelvucitabine
Dexelvucitabine
IUPAC name
4-Amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
Other names
Reverset
Identifiers
CAS number 134379-77-4 YesY
PubChem 64973
KEGG D03981 YesY
Jmol-3D images Image 1
Properties
Molecular formula C9H10FN3O3
Molar mass 227.19 g/mol
 YesY (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Dexelvucitabine is a failed experimental agent for the treatment of HIV. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.

On April 3, 2006, Pharmasset and Incyte Corporation, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia in a phase II trial.

v · d · eAntiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Entry/fusion inhibitors
(Discovery & development)
gp41 (Enfuvirtide) • CCR5 (Maraviroc, Vicriviroc†, Cenicriviroc†, PRO 140†) • CD4 (Ibalizumab†)
Reverse-transcriptase
inhibitors (RTIs)

Nucleoside analogues/NARTIs: Abacavir (ABC)°# • Emtricitabine (FTC)°# • Lamivudine (3TC)°# • Didanosine (ddI)# • Zidovudine (AZT)# • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Amdoxovir†• Stavudine (d4T)# • Zalcitabine (ddC)◊ • Festinavir† 

Nucleotide analogues/NtRTIs: Tenofovir°#
Non-Nucleoside (NNRTI)
(Discovery & development)
(1st generation) Efavirenz°# • Nevirapine#  • Loviride◊ • Delavirdine◊ •
 (2nd generation) diarylpyrimidines (Etravirine, Rilpivirine)  • Lersivirine†
Integrase inhibitors
Raltegravir • Elvitegravir† • Dolutegravir† • Globoidnan A (experimental)  • MK-2048†  • BI 224436†  
Maturation inhibitors
Bevirimat† • Vivecon†
Protease Inhibitors (PI)
(Discovery and development)
1st generation
Fosamprenavir° • Lopinavir°# • Nelfinavir# • Ritonavir# • Saquinavir# • Amprenavir◊ • Indinavir◊#
2nd generation
Combined formulations
Lamivudine/zidovudine • Emtricitabine/tenofovir/efavirenz • Abacavir/lamivudine/zidovudine • Tenofovir/emtricitabine • Lopinavir/ritonavir • Abacavir/lamivudine • Emtricitabine/rilpivirine/tenofovir
Experimental agents
TRIM5alpha (gene)
Tat antagonists
Trichosanthin
Other
Failed agents
Dexelvucitabine • Capravirine • Emivirine • Lodenosine • Atevirdine • Brecanavir • Aplaviroc
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III °DHHS preferred first-line agent. ◊Formerly or rarely used agent.

M: VIR

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drugJ(dnaa, rnaa, rtva, vacc)
Stub icon This antiinfective drug article is a stub. You can help Wikipedia by expanding it.